Strong Third Quarter Revenue Growth
Repligen reported a 10% year-over-year sales growth and 6% order growth despite seasonal headwinds. Non-COVID sales were up 3% versus the last quarter, indicating strong market conditions.
Record Revenue in New Modalities
The company achieved a record revenue quarter for new modalities, with sales up more than 20% year-over-year and orders up low double digits compared to Q3 2023.
Improved CDMO Performance
CDMO revenue and orders grew approximately 20% year-over-year, recovering to 2022 levels. The business rebounded with orders up mid-teens over the last two quarters compared to the same period last year.
Strong Regional Growth Excluding China
North America and Asia (excluding China) showed strong sales growth, with Asia up more than 40% year-over-year.
Increased 2024 Financial Guidance
Repligen tightened its revenue guidance range to $630 million to $639 million for 2024, with an increase in gross margin guidance to 49.5% to 50.5%.